Evidence map›Paper›PMID 38288345›Full record

ArticleOsteoarthritis and cartilage open2024

Ileana Marrero-Berrios, S Elina Salter, Rishabh Hirday, Charles P Rabolli, Andrea Tan, Clark T Hung, Rene S Schloss, Martin L Yarmush

Open access · goldAbstract read
In one paragraph

Article in Osteoarthritis and cartilage open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ileana Marrero-BerriosDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
S Elina SalterDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
Rishabh HirdayDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
Charles P RabolliDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
Andrea TanDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Clark T HungDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Rene S SchlossDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
Martin L YarmushDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA.
Rutgers, The State University of New Jersey · USColumbia University · US

Funding

Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gordana Vunjak-Novakovic · 2019 to 2026
$12.6M
UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
Incorporation of Dexamethasone Delivery within Engineered CartilageR01AR068133 · NIAMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HUNG, CLARK T. · 2016 to 2021
$2.8M
NIAMS NIH HHS R01 AR068133NIBIB NIH HHS P41 EB027062NIGMS NIH HHS T32 GM008339
6 · The paper itself

Abstract

Objective: Osteoarthritis (OA) is a chronic joint disease, with limited treatment options, characterized by inflammation and matrix degradation, and resulting in severe pain or disability. Progressive inflammatory interaction among key cell types, including chondrocytes and macrophages, leads to a cascade of intra- and inter-cellular events which culminate in OA induction. In order to investigate these interactions, we developed a multi-cellular Methods: We compared macrophages, chondrocytes and their co-culture responses to "low" Interleukin-1 (IL-1) or "high" IL-1/tumor necrosis factor (IL-1/TNF) levels of inflammation. We also investigated response changes following the administration of dexamethasone (DEX) or mesenchymal stromal cell (MSC) treatment via a combination of gene expression and secretory changes, reflecting not only inflammation, but also chondrocyte function. Results: Inflamed chondrocytes presented an osteoarthritic-like phenotype characterized by high gene expression of pro-inflammatory cytokines and chemokines, up-regulation of ECM degrading proteases, and down-regulation of chondrogenic genes. Our results indicate that while MSC treatment attenuates macrophage inflammation directly, it does not reduce chondrocyte inflammatory responses, unless macrophages are present as well. DEX however, can directly attenuate chondrocyte inflammation. Conclusions: Our results highlight the importance of considering multi-cellular interactions when studying complex systems such as the articular joint. In addition, our approach, using a panel of both inflammatory and chondrocyte functional genes, provides a more comprehensive approach to investigate disease biomarkers, and responses to treatment.

Indexed as

ChrondrocytesCytokineDexamethasoneGene expressionIn vitroMacrophagesMSCOsteoarthritis

Identifiers

PMID38288345
PMCPMC10823137
OpenAlexW4390613890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.